Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 10/2017

03.08.2017 | Original Article

An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival

verfasst von: Steven Walczak, Vic Velanovich

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aims to evaluate the development of an artificial neural network (ANN) method for predicting the survival likelihood of pancreatic adenocarcinoma patients. The ANN predictive model should produce results with a 90% sensitivity.

Methods

A prospective examination of the records for 283 consecutive pancreatic adenocarcinoma patients is used to identify 219 records with complete data. These records are then used to create two unique samples which are then used to train and validate an ANN predictive model. Numerous network architectures are evaluated, following recommended ANN development protocols.

Results

Several backpropagation-trained ANNs were produced that satisfied the 90% sensitivity requirement. An ANN model with over a 91% sensitivity is selected because even though it did not have the highest sensitivity, it was able to achieve over 38% specificity.

Conclusions

ANN models can accurately predict the 7-month survival of pancreatic adenocarcinoma patients, both with and without resection, at a 91% sensitivity and 38% specificity. This implies that ANN models may be useful objective decision tools in complex treatment decisions. This information may be used by patients and surgeons in determining optimal treatment plans that minimize regret and improve the quality of life for these patients.
Literatur
1.
Zurück zum Zitat Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075–84.CrossRefPubMed Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075–84.CrossRefPubMed
2.
Zurück zum Zitat Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 2005;14:1766–73.CrossRef Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 2005;14:1766–73.CrossRef
3.
Zurück zum Zitat Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006;17:403–9.CrossRefPubMed Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006;17:403–9.CrossRefPubMed
4.
Zurück zum Zitat Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, Van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549–58.CrossRefPubMed Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, Van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549–58.CrossRefPubMed
5.
Zurück zum Zitat Bradley EL III. Long-term survival after pancreaticoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas 2008;37:349–351CrossRefPubMed Bradley EL III. Long-term survival after pancreaticoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas 2008;37:349–351CrossRefPubMed
6.
Zurück zum Zitat McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, Anderson FA, Tseng JF. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007;246:246–53.CrossRefPubMedPubMedCentral McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, Anderson FA, Tseng JF. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007;246:246–53.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Vollmer CM, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, Callery MP, Pancreatic Surgery Mortality Study Group. A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012;16:89–103. Vollmer CM, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, Callery MP, Pancreatic Surgery Mortality Study Group. A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012;16:89–103.
8.
Zurück zum Zitat Miura T, Hirano S, Nakamura T, et al. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study. Surgery 2014;155:457–467CrossRefPubMed Miura T, Hirano S, Nakamura T, et al. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study. Surgery 2014;155:457–467CrossRefPubMed
9.
Zurück zum Zitat Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg 2009;13:26–34CrossRefPubMed Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg 2009;13:26–34CrossRefPubMed
10.
Zurück zum Zitat Joliat GR, Peterman D, Demartines N, Schafer M. External assessment of the Early Mortality Risk Score in patient with adenocarcinoma undergoing pancreaticoduodenectomy. HPB 2015;17:605–610CrossRefPubMedPubMedCentral Joliat GR, Peterman D, Demartines N, Schafer M. External assessment of the Early Mortality Risk Score in patient with adenocarcinoma undergoing pancreaticoduodenectomy. HPB 2015;17:605–610CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Dasari BV, Roberts KJ, Hodson J, et al. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. HPB 2016;18:332–338CrossRefPubMedPubMedCentral Dasari BV, Roberts KJ, Hodson J, et al. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. HPB 2016;18:332–338CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat de Geus SW, Evans DB, Bliss LA, et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis. Eur J Surg Oncol 2016;42:1552–1560CrossRefPubMed de Geus SW, Evans DB, Bliss LA, et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis. Eur J Surg Oncol 2016;42:1552–1560CrossRefPubMed
13.
Zurück zum Zitat Jamal MH, Doi SA, Moser AJ, et al. McGill Brisbane System Score for patients with resectable pancreatic head adenocarcinoma. World J Gastroenterol 2014 20:12226–12232CrossRefPubMedPubMedCentral Jamal MH, Doi SA, Moser AJ, et al. McGill Brisbane System Score for patients with resectable pancreatic head adenocarcinoma. World J Gastroenterol 2014 20:12226–12232CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Regulin-Coyne E, Carrooll JE, Smith JK, et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery 2012;152(3 Suppl 1):S120-S127CrossRef Regulin-Coyne E, Carrooll JE, Smith JK, et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery 2012;152(3 Suppl 1):S120-S127CrossRef
15.
Zurück zum Zitat Abott DE, Tzeng CW, Merkow RP, et al. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 2013;20 Suppl 3:S500-S508CrossRef Abott DE, Tzeng CW, Merkow RP, et al. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 2013;20 Suppl 3:S500-S508CrossRef
16.
Zurück zum Zitat Sutton JM, Wilson GC, Paquette IM, et al. Cost-effectiveness after pancreaticoduodenectomy: bolstering the volume argument. HPB 2014;16:1056–1061CrossRefPubMedPubMedCentral Sutton JM, Wilson GC, Paquette IM, et al. Cost-effectiveness after pancreaticoduodenectomy: bolstering the volume argument. HPB 2014;16:1056–1061CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Morris S, Gurusamy KS, Sherringham J, Davidson BR. Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and perampullary cancer. BMC Gastroenterol 2015 15:44CrossRefPubMedPubMedCentral Morris S, Gurusamy KS, Sherringham J, Davidson BR. Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and perampullary cancer. BMC Gastroenterol 2015 15:44CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Velanovich V. The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas 2011;40:1063–9CrossRefPubMed Velanovich V. The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas 2011;40:1063–9CrossRefPubMed
19.
Zurück zum Zitat Mogal H, Vermilion SA, Dodson R, et al. Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2017;24:1714–1721CrossRefPubMed Mogal H, Vermilion SA, Dodson R, et al. Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2017;24:1714–1721CrossRefPubMed
20.
Zurück zum Zitat Hernandez JM, Tsalatsanis A, Humphries LA, et al. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg 2014;259:1208–14CrossRefPubMed Hernandez JM, Tsalatsanis A, Humphries LA, et al. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg 2014;259:1208–14CrossRefPubMed
21.
Zurück zum Zitat Shin SA, Kim SC, Hong SM, et al. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following resection? Clinicopathological analysis of 82 long-term survivors. Pancreas 2014;43:571–577CrossRefPubMed Shin SA, Kim SC, Hong SM, et al. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following resection? Clinicopathological analysis of 82 long-term survivors. Pancreas 2014;43:571–577CrossRefPubMed
22.
Zurück zum Zitat Lisboa PJ, Taktak AF. The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw 2006;19:408–15.CrossRefPubMed Lisboa PJ, Taktak AF. The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw 2006;19:408–15.CrossRefPubMed
23.
Zurück zum Zitat Bollschweiler EH, Mönig SP, Hensler K, et al. Artificial neural network for prediction of lymph node in gastric cancer: a phase II diagnostic study. Ann Surg Oncol 2004;11:506–11.CrossRefPubMed Bollschweiler EH, Mönig SP, Hensler K, et al. Artificial neural network for prediction of lymph node in gastric cancer: a phase II diagnostic study. Ann Surg Oncol 2004;11:506–11.CrossRefPubMed
24.
Zurück zum Zitat Pofahl WE, Walczak SM, Rhone E, Izenberg SD. Use of an artificial neural network to predict length of stay in acute pancreatitis. Am Surg 1998;64:868–72.PubMed Pofahl WE, Walczak SM, Rhone E, Izenberg SD. Use of an artificial neural network to predict length of stay in acute pancreatitis. Am Surg 1998;64:868–72.PubMed
25.
Zurück zum Zitat Santos-Garcıa G, Varela G, Novoa N, Jiménez MF. Prediction of postoperative morbidity after lung resection using an artificial neural network ensemble. Art Intell Med 2004;30:61–9.CrossRef Santos-Garcıa G, Varela G, Novoa N, Jiménez MF. Prediction of postoperative morbidity after lung resection using an artificial neural network ensemble. Art Intell Med 2004;30:61–9.CrossRef
26.
Zurück zum Zitat Syed Z, Rubinfeld I, Patton JH, et al. Using procedural codes to supplement risk adjustment: a nonparametric learning approach. J Am Coll Surg 2011;212:1086–93.CrossRefPubMed Syed Z, Rubinfeld I, Patton JH, et al. Using procedural codes to supplement risk adjustment: a nonparametric learning approach. J Am Coll Surg 2011;212:1086–93.CrossRefPubMed
27.
Zurück zum Zitat Bartosch-Härlid A, Andersson B, Aho U, et al. Artificial neural networks in pancreatic disease. Br J Surg 2008;95:817–26.CrossRefPubMed Bartosch-Härlid A, Andersson B, Aho U, et al. Artificial neural networks in pancreatic disease. Br J Surg 2008;95:817–26.CrossRefPubMed
28.
Zurück zum Zitat Swanson RS, Pezzi CM, Mallin K, et al. The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the National Cancer Data Base. Ann Surg Oncol 2014;21:4059–67CrossRefPubMed Swanson RS, Pezzi CM, Mallin K, et al. The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the National Cancer Data Base. Ann Surg Oncol 2014;21:4059–67CrossRefPubMed
29.
Zurück zum Zitat Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–94CrossRefPubMed Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–94CrossRefPubMed
30.
Zurück zum Zitat Walczak S, Cerpa N. Heuristic principles for the design of artificial neural networks. Inf Softw Technol 1999;41:107–17CrossRef Walczak S, Cerpa N. Heuristic principles for the design of artificial neural networks. Inf Softw Technol 1999;41:107–17CrossRef
31.
Zurück zum Zitat Zhang GP. Avoiding pitfalls in neural network research. IEEE Trans Syst Man Cybern Part C Appl Rev. 2007;37:3–16CrossRef Zhang GP. Avoiding pitfalls in neural network research. IEEE Trans Syst Man Cybern Part C Appl Rev. 2007;37:3–16CrossRef
32.
Zurück zum Zitat Barnard, E., & Wessels, L. F. A. (1992). Extrapolation and interpolation in neural network classifiers. IEEE Control Syst, 12(5), 50–53.CrossRef Barnard, E., & Wessels, L. F. A. (1992). Extrapolation and interpolation in neural network classifiers. IEEE Control Syst, 12(5), 50–53.CrossRef
33.
Zurück zum Zitat Specht, D. F. (1991). A general regression neural network. IEEE Trans Neural Netw, 2(6), 568–576.CrossRefPubMed Specht, D. F. (1991). A general regression neural network. IEEE Trans Neural Netw, 2(6), 568–576.CrossRefPubMed
34.
Zurück zum Zitat De Villiers, J., & Barnard, E. (1993). Backpropagation neural nets with one and two hidden layers. IEEE Trans Neural Netw, 4(1), 136–141.CrossRefPubMed De Villiers, J., & Barnard, E. (1993). Backpropagation neural nets with one and two hidden layers. IEEE Trans Neural Netw, 4(1), 136–141.CrossRefPubMed
35.
Zurück zum Zitat Sexton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 2011;253:1223–1229CrossRef Sexton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 2011;253:1223–1229CrossRef
36.
Zurück zum Zitat Velanovich V, Wollner I. Quality of life and performance status in patients with pancreatic and periampullary tumors. Int J Clin Oncol 2011;16:401–407CrossRefPubMed Velanovich V, Wollner I. Quality of life and performance status in patients with pancreatic and periampullary tumors. Int J Clin Oncol 2011;16:401–407CrossRefPubMed
37.
Zurück zum Zitat Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.CrossRefPubMed Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.CrossRefPubMed
38.
Zurück zum Zitat Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010;17:2092–101.CrossRefPubMed Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010;17:2092–101.CrossRefPubMed
39.
Zurück zum Zitat Robinson DW Jr, Eisenberg DF, Cella D, Zhao N, de Boer C, DeWitte M. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 2008;6:283–90.PubMed Robinson DW Jr, Eisenberg DF, Cella D, Zhao N, de Boer C, DeWitte M. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 2008;6:283–90.PubMed
40.
Zurück zum Zitat Walczak S. Evaluating medical decision making heuristics and other business heuristics with neural networks. In Intelligent decision making: an AI-based approach, pp. 259–287, Springer Berlin, Heidelberg, 2008. Walczak S. Evaluating medical decision making heuristics and other business heuristics with neural networks. In Intelligent decision making: an AI-based approach, pp. 259–287, Springer Berlin, Heidelberg, 2008.
Metadaten
Titel
An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival
verfasst von
Steven Walczak
Vic Velanovich
Publikationsdatum
03.08.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 10/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3518-7

Weitere Artikel der Ausgabe 10/2017

Journal of Gastrointestinal Surgery 10/2017 Zur Ausgabe

Evidence Based Current Surgical Practice

Management of Diverticulitis in 2017

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.